Nachrichten zur Biomarin Pharmaceutical Inc. Aktie

…

BioMarin (BMRN) delivered earnings and revenue surprises of -18.96% and +0.50%, respectively, for the quarter ended March 2026. Do the…

…

A number of stocks fell in the afternoon session after reports revealed that the US may impose up to 100%…

Detailed price information for Hims & Hers Health Inc (HIMS-N) from The Globe and Mail including charting and trades.…

What Happened? A number of stocks fell in the afternoon session after reports revealed that the US may impose up…

Hims & Hers Health, Regeneron, Biogen, BioMarin Pharmaceutical, and Moderna Shares Are Falling, What You Need To Know…

Investors need to pay close attention to BioMarin Pharmaceutical stock based on the movements in the options market lately.…

BioMarin (BMRN) delivered earnings and revenue surprises of +85.48% and +5.41%, respectively, for the quarter ended December 2025. Do the…

Lets take a closer look at what awaits Bausch Health, Amicus Therapeutics, BioMarin Pharmaceutical, Insmed and Madrigal Pharmaceuticals as they…

Vancouver (www.aktiencheck.de) - BioMarin Pharmaceutical-Aktienanalyse von Canaccord Genuity:Die Analysten von Canaccord haben die BioMarin Pharmaceutical-Aktie (ISIN: US09061G1013, WKN: 924801, Ticker-Symbol:…

Whether youre a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top…

Whether youre a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top…

…

Charlotte, NC (www.aktiencheck.de) - BioMarin Pharmaceutical-Aktienanalyse von Truist:Truist-Analyst Joon Lee habe das Kursziel für die BioMarin Pharmaceutical-Aktie (ISIN: US09061G1013, WKN:…

New York (www.aktiencheck.de) - BioMarin Pharmaceutical-Aktienanalyse von H.C. Wainwright & Co.:Die Analysten von H.C. Wainwright haben das Kursziel für BioMarin…

Dimerix Ltd (ASX:DXB, OTC:SBMJF) has flagged that its US commercial licensing agreement for DMX-200 remains intact following BioMarin Pharmaceutical’s move...…

…

…

BioMarin Pharmaceutical said on ?Friday it would acquire Amicus ?Therapeutics ?for about $4.8 ?billion, expanding its presence in rare metabolic…

Key PointsCalifornia-based Palo Alto Investors acquired 997,698 DYN shares in the third quarter. Overall, the position value increased by $13.5…

Although the company recorded higher sales overall, its decided to divest one of its products.…

Image source: The Motley Fool.DateOct. 27, 2025, 4:30 p.m. ETCall participantsPresident and Chief Executive Officer — Alexander HardyChief Financial Officer…

…

BioMarin (BMRN) delivered earnings and revenue surprises of +39.81% and +7.72%, respectively, for the quarter ended June 2025. Do the…

Whether youre a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top…

Whether youre a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top…

BOSTON, June 20, 2025 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) today announced that it has postponed…

Investors need to pay close attention to BioMarin Pharmaceutical stock based on the movements in the options market lately.…

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.…

Whether youre a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top…

…

Whether youre a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top…

Top-ranked stocks Doximity (DOCS), Life Time Group Holdings (LTH), Adtalem Global Education (ATGE), BioMarin Pharmaceutical (BMRN) and Iridium Communications (IRDM)…

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Heres why…

BioMarin Pharmaceutical Inc. (BMRN) fokussiert sich auf die Entwicklung und Vermarktung von innovativen Therapien für seltene genetische Erkrankungen. Das Unternehmen…

Das Biotechnologieunternehmen Biomarin Pharmaceutical verzeichnete im vierten Quartal einen bemerkenswerten Erfolg. Der Nettogewinn stieg deutlich auf 125 Millionen Dollar, was…

BioMarin (BMRN) delivered earnings and revenue surprises of 26.03% and 4.97%, respectively, for the quarter ended December 2024. Do the…

BioMarin (BMRN) doesnt possess the right combination of the two key ingredients for a likely earnings beat in its upcoming…

…

…

…

St. Petersburg (www.aktiencheck.de) - BioMarin Pharmaceutical-Aktienanalyse von BMO Capital Markets: Raymond James hat die Berichterstattung über BioMarin Pharmaceutical Inc. (ISIN: US09061G1013,…

New York (www.aktiencheck.de) - Rating-Update: Die Analysten von Sanford C. Bernstein & Co bewerten die BioMarin Pharmaceutical-Aktie (ISIN: US09061G1013, WKN: 924801,…

Toronto (www.aktiencheck.de) - Rating-Update: George Farmer, Analyst der Scotiabank, bekräftigt das "sector perform"-Votum für die BioMarin Pharmaceutical-Aktie (ISIN: US09061G1013, WKN: 924801,…

Toronto (www.aktiencheck.de) - BioMarin Pharmaceutical-Aktienanalyse von RBC Capital Markets: Aktuelle Bewertung RBC Capital hat das Kursziel für BioMarin Pharmaceutical Inc. (ISIN: US09061G1013,…

Charlotte (www.aktiencheck.de) - BioMarin Pharmaceutical-Aktienanalyse von BofA Securities: Aktuelle Situation Jason Zemansky, Analyst von BofA Securities, hat das Kursziel für BioMarin Pharmaceutical…

St. Louis (www.aktiencheck.de) - BioMarin Pharmaceutical-Aktienanalyse von Stifel: Aktuelle Situation Die Analysten von Stifel haben das Kursziel für BioMarin Pharmaceutical Inc. (ISIN:…

San Francisco (www.aktiencheck.de) - BioMarin Pharmaceutical-Aktienanalyse von Wells Fargo Advisors: Wells Fargo hat das Kursziel für die Aktien von BioMarin Pharmaceutical…

…